An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3)
An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3)
Cerebrotendinous xanthomatosis
Intervention name : FPF1011 INN of the intervention : Chenodeoxycholic acid Dosage And administration of the intervention : Dose of chenodeoxycholic acid is 750 mg/day for patients aged 20 or older, and 15 mg/kg/day under ages 20, administered orally in three divided doses a day. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : FPF1011 INN of the intervention : Chenodeoxycholic acid Dosage And administration ...
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acidin Adult and Pediatric Patients With ...
Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acidfor C ...
Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)